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Abstract 
This study examines direct-to-consumer genetic testing (DTCGT) in the UK 
using the Social Construction of Technology (SCOT) framework to draw 
conclusions about how commercial genotyping is being shaped by principal 
groups involved with the technology. Different tests are available including 
single nucleotide polymorphism (SNP) genotyping for ancestry and health 
information, the latter being the focus of this study. I conducted interviews 
with DTCGT users and genetics clinicians who had either been consulted 
about DTCGT or who were willing to discuss their views. This paper is about 
one of the study’s three themes, the NHS. DTCGT seemed to provide a point 
of focus for conflict between personalised and collective medicine in the UK, 
rather than being its cause. This suggests that DTCGT is more likely to 
achieve stability by virtue of being superseded by new technologies, rather 
than by achieving closure. 
 
Introduction 
DTCGT has been available for purchase on the Internet for ten years. The 
DTCGT market offers numerous types of test; the focus for this project is the 
testing that claims to provide information about individual risk for common 
complex diseases. These tests are often sold as part of a genome-wide scan 
of hundreds of thousands of single nucleotide polymorphisms (SNPs), also 
known as SNP genotyping, that provide information on a range of traits 
including ancestry, physical traits, genetic disease, carrier status and 
pharmacogenomics as well as common complex disease risk (Leachman et 
al 2011).  
Facilitated by convergent developments in biotechnology, information 
technology and the Internet (Wright et al 2011), DTCGT capitalises on 
neoliberal policies that emphasise individual consumerism. The effect of 
these policies on health care has been to devolve responsibility for health to 
individuals resulting in a group of autonomous consumers of healthcare 
services. Individuals are being encouraged to exercise accountability by 
managing their health and the risks to it, which DTCGT marketing capitalises 
on (Tutton and Prainsack 2011). Knowledge that was previously the 
preserve of genetics clinicians, imparted in controlled clinical environments, 
has been democratised and made available to the public without recourse to 
the medical establishment (Borry et al 2010). Companies’ marketing tactics 
employ tropes of personalisation to emphasise the advantages of information 
for making life-style and health choices in an autonomous, confidential 
manner (Arribas-Ayllon et al 2011). However, despite companies’ astute 
marketing there are powerful counterclaims about the accuracy of the 
science on which genotyping is based (Janssens et al 2008). There are also 
concerns about the public’s ability to understand the risk information they are 
sold without genetic counselling (Collins et al 2011). In addition health 
professionals’ accountability to patients is challenged by their misgivings 
about the utility and potential harm that the information from commercial 
SNP genotyping could cause (Kraft and Hunter 2009). DTCGT is particularly 
problematic in this regard because of the capacity of genetic knowledge to 
cause harm to the individual and also to their relatives. So whilst the privacy 
and opportunity to exercise autonomy associated with DTCGT are presented 
as positive attributes by some (Juengst et al 2012), the potential 
consequences of any breach of confidentiality could be severe (Finlay et al 
2016). These potentially divergent views about DTCGT represent the kind of 
challenge to society’s moral order that formed the basis of the calls for 
regulation of commercial genomics and its lack of stabilisation as a 
technology (Evans and Green 2009). Thus DTCGT can be seen as a 
contested technology, which this study sought to examine in the UK context. 
 
Background  
Early research into DTCGT mostly comprised analyses of website material 
or surveys as to who might engage with DTCGT or how they might interpret 
results, rather than directly investigating the impact of DTCGT per se. 
Website analyses by Lachance et al (2010) and Singleton et al (2012) found 
a predictable bias towards positioning the benefits of testing, rather than a 
balanced presentation of advantages and disadvantages or limitations of 
testing. Content was variable within and across different sites, which could 
appear confusing and difficult to understand for some. Saukko et al (2010) 
undertook a qualitative analysis of nutrigenomic testing websites. 
Nutrigenomics companies sell supplements on the basis of genotyping a 
more limited range of SNPs thought to relate to metabolism rather than 
common complex disease risk, but this study’s findings appear applicable to 
the wider commercial genomics market. The study is noteworthy because 
the authors suggested that the boundary work performed by regulators and 
researchers to separate medical testing from commercial genomics is 
circumvented by companies who legitimise their products by positioning 
them as lifestyle products. Whilst companies selling SNP genotyping for 
common complex disease risk, ancestry and physical characteristics are not 
using testing to sell other products, their tropes of empowerment to enable 
positive lifestyle choices seem similarly designed. This is highlighted in an 
analysis of the discourse on websites for the three main personal genomics 
companies in 2007-2010, deCODEme, Navigenics and 23andMe. Whilst 
there were differences between all three websites, consumer empowerment 
was a common trope, suggesting that personalised health information could 
facilitate healthier lifestyle choices and thus reduce disease risk. The authors 
suggest that marketing rhetoric promising greater self-knowledge to alleviate 
future risk manages to obscure the uncertainty associated with SNP 
genotyping data (Arribas Ayllon et al 2011). 
 
Early survey research investigated what motivated people to consider 
testing, how they might interpret test results and whether information about 
the risks and limitations of testing would influence their decisions. Women 
with a history or family history of breast or ovarian cancer were found to 
choose testing less frequently when the risks of testing were included in 
mock websites. These findings suggest that the positive framing of DTCGT 
websites, as illustrated by the website analysis studies cited above, may 
attract the unwary with a concern about their health history (Gray et al 2009). 
McGuire et al (2009) surveyed Facebook users in the United States of 
America (USA) (though not through Facebook) about DTCGT. Almost half of 
the cohort was aware of DTCGT, although fewer than 10% had tested. 
However, two thirds of respondents suggested that they would consider 
testing and a third indicated that they equated testing with diagnostic 
information. Whilst an indication does not equate to action, these results 
prompted the authors to conclude that healthcare services needed to 
prepare to be consulted by DTCGT users seeking advice about test results. 
Adding to concerns about this increased demand on health services, a UK-
based survey of people on the TwinsUK register established that, while a 
much smaller proportion of survey respondents in the UK claimed to be 
aware of DTCGT, enough would consider testing (depending on the price) to 
prompt similar warnings about the impact on healthcare providers (Cherkas 
et al 2010). A survey by Leighton et al (2012), which compared Facebook 
users’ interpretation of mock test results with those of genetics counsellors in 
the USA, found that whilst the Facebook users found the results easy to 
understand, they interpreted their meaning differently from the genetics 
counsellors. The authors suggested that people require support to 
understand the nature of testing information.  
 
The first published empirical work involving users of DTCGT was McGowan 
et al’s (2010) study in the USA. They found that these early adopters were 
curious about their genomes, knowledgeable about genetics and did not 
appear to suffer harm as a result of their test results nor make any significant 
changes to their lifestyle. These findings were confirmed by later studies of 
genotyping test users including a mixed methods study of early adopters in 
Switzerland (Vayena et al 2012). More recently the longitudinal PGen study 
conducted by George Church’s group in Boston surveyed users of DTCGT 
(Carere et al 2016). They found that this cohort’s understanding of genetics 
was also relatively high before and after testing but their confidence in 
applying their genetics knowledge was reduced after testing, possibly as a 
result of their experience of receiving results. However, in line with studies 
outlined above, users did not report any increased anxiety after testing. 
 
However, despite the considerable literature about DTCGT published by 
scientific genetics, medical, ethics, law and sociology communities, at the 
time of commencement of this study the experience of DTCGT in the United 
Kingdom (UK) represented a metaphorical “black box” (Lynch et al 2010, 
Bijker et al 2012). Accordingly I chose to investigate DTCGT in the UK 
context using Pinch and Bijker’s Social Construction of Technology (SCOT) 
model. The choice of framework is deliberate, as my intention is to shed light 
on the arguments and contested nature of DTCGT, specifically examining 
relevant social actors’ experiences within the wider context of the UK’s 
National Health Service, as I shall explain. 
 
Using SCOT to examine DTCGT in the UK healthcare context 
Rather than simply viewing SNP genotyping as a laboratory test, the 
competing claims and discourses it provokes indicate that DTCGT warrants 
analysis as an assemblage that is being socially constructed and shaped by 
the discourses and actions of the actors involved with it. In this context 
discourses are understood as practices of sharing and developing beliefs 
and understanding through discussion, evaluation and interpretation in order 
to produce knowledge about the technology (Lessa 2006). In SCOT these 
principles are applied to  
• relevant social groups of actors, in this case test users resident in the 
UK and NHS genetics clinicians  
• the wider social context, in this case the NHS  
• actors’ interpretative flexibility 
• the stabilisation and closure of disputes surrounding the technology 
(Bijker et al 2012). 
In their critical review of SCOT, Klein and Kleinman argue that assuming 
relevant social groups are homogeneous misses the potential influence that 
individuals may have on technology owing to their political, economic or 
professional influence (Klein and Kleinman 2002). They advocate for more 
detailed analysis of the constituent members of relevant social groups whilst 
also paying attention to the wider context for a more comprehensive 
analysis. Accordingly I shall describe the characteristics of participants in the 
users’ and genetics clinicians’ groups in the methods section. 
 
The use of SCOT illustrates the influence of human intervention on SNP 
genotyping in the UK, which is crucial to challenge deterministic views. A 
technologically deterministic position could absolve people from 
responsibility in their engagement with the technology (Wyatt 2008), while a 
bioethical one could assume a paternalistic interpretation, which risks 
interpreting findings in a non-symmetrical manner. Given the potential impact 
of genetic information on people and their social groups, an exploration of 
the social construction of this technology seems to provide a germane 
approach to understanding the impact of DTCGT in the UK.  
 
Thus the wider social context of the UK and, more specifically, the NHS is 
central. From its inception in 1948 the NHS has provided care free at the 
point of access to UK citizens on the basis of a collective medical model. The 
medical profession has influenced NHS patients’ access to health 
interventions relying on patients to trust that this is decided in their best 
interests. This has increasingly translated into rationing and policy shifts 
associated with economising and the public taking responsibility for their 
health to discourage dependency on the NHS (Department of Health 2010, 
Klein 2013). Healthcare professionals’ gatekeeping role and formerly 
sacrosanct expertise is arguably challenged by people’s direct access to 
health information, altering trust-based professional-patient relationship 
(Tutton 2014). The original collective medical model is shifting from what 
Klein calls the paternalistic “church”, where care is dispensed to a trusting 
public, to the consumerist “garage” to which people drop in and take what 
they want (Klein 2013: 306). Thus the NHS’ iconic status in British culture, 
representing democracy and the welfare state (Busby and Martin 2006), is 
increasingly challenged by demands from medical innovation, societal 
expectation for personalisation and reduced funding owing to political 
incentives for austerity (Bambra 2013).  
 
Genomics exemplifies the individual, particularly in relation to human 
genomics, which has provided DTCGT companies with the basis for focusing 
their marketing on personalisation and individual responsibility. This aligns 
with the simultaneous globalisation of neoliberal ideas including emphasis on 
individual choice and consumerism, tropes that DTCGT companies 
foreground (Arribas Ayllon et al 2011). This polarisation of collective and 
individual is considered by Donna Dickenson. She suggests the DTCGT 
companies’ tropes of personalisation in the name of empowerment and 
individual responsibility for health undermines collective medicine in an 
increasingly commercial domain (Dickenson 2013). The contradiction 
inherent in DTCGT companies’ marketing personalised health information on 
the basis of population-derived genomic data is central to her argument that 
commercial genomics is simply profiteering. This is despite the collapse or 
takeover of many DTCGT companies which suggests failure in that regard 
otherwise (Vorhaus 2012).  
 
These interdependent but conflicting aspects of collective and individualised 
medicine are emblematic of this study. Thus the study focuses on users and 
genetics clinicians as the two relevant social groups influencing DTCGT 
within the social context of the NHS. Interpretative flexibility is key for 
illuminating the influence of different views of technology presented to 
different audiences, at different times with different intentions and outcomes 
(Bijker et al 2012). Whilst Williams and Edge (1996) argue that the infinite 
possibilities that could be proposed are unhelpful in analysing how closure is 
achieved, analysis of variations in accounting can be particularly valuable 
when claims are repeatedly disputed (Potter and Mulkay 1985). The concept 
is thus important for this study, as inconsistent and contradictory views are 
evident in the data. 
 
In order to understand the impact of DTCGT in the UK I collected and 
analysed the stories, experiences and thoughts of two relevant social groups 
involved with the technology in the UK. The findings discussed in this paper 
focus on the tension between personalised and collective medicine that 
DTCGT creates, one of the three themes evident in the study’s data. 
 
Methods 
DTCGT was relatively novel and un-researched in the UK context at the time 
this study commenced. The SCOT framework was chosen to illuminate how 
the relevant social groups of test users and genetic clinicians engage with 
DTCGT in different and competing ways for social, economic, professional 
and regulatory reasons. It was obvious to involve test users resident in the 
UK as one of the relevant social groups, owing to their direct experiential 
knowledge of DTCGT and the potential for them to seek help from NHS 
genetics services. Literature related to DTCGT suggested that genetics 
clinicians would have influential views and shared understandings about 
DTCGT owing to their clinical specialism. These were likely to contrast with 
views of users’ or producers’ of the technology so these practitioners were 
involved as the other relevant social group for the study. In addition, with 
their status as experts in clinical genetics, they would be most likely to be 
called upon to interpret results and provide counselling in the event of any 
concern. Both groups have interests in DTCGT technology and each shares 
experience and knowledge of DTCGT, which Bijker refers to as a 
“technological frame” (Bijker 2010:69). But their conflicting interpretations 
and knowledge claims provide a suitable starting point for examining the 
influence of their interests on the technology (Bartley 1990). 
 
The other group of healthcare professionals that could be relevant in the UK 
context is General Practitioners (GPs); their role as gatekeepers for 
specialist consultations in the UK (Louden 2008) indicates that they are likely 
to be users’ first port of call for help with interpretation of health test 
information. However, as the literature indicates lack of understanding of 
genomics by most doctors, genetics clinicians presented a more relevant 
group, given their experience of advising and supporting people in relation to 
genetic conditions (Edleman and Eng 2009, Salari 2009). 
 
With approvals from Research Ethics and Research and Development 
committees in place, I sought participants for the study. To be eligible to 
participate, users had to be an adult UK resident and have purchased 
DTCGT that included health information. This purposeful sampling was 
intended to facilitate discussion about their engagement with the technology 
and their views on the relationship of the health-related aspects to their 
health care in the NHS context. I purposely used the Internet to recruit users. 
At the time of the study personal genotyping was largely marketed and sold 
online; I hoped that test users would be conversant with finding information 
about genomics online and would come across invitations to be involved in 
research. However, unlike genetics clinicians whose geographical locations 
could be easily established, DTCGT users were people who Brown and 
Webster describe as being without embodiment (Brown and Webster 2004). 
This is due to their identities as DTCGT users being linked to their online 
personas rather than their physical, embodied ones. I thus anticipated having 
to use several approaches to recruit participants to this group.  
 
Recruitment of users was surprisingly easy however. A webpage describing 
the study (now removed) and a blog post on “genomesunzipped”, a website 
providing independent, expert commentary on commercial genomics 
requested volunteers (http://www.genomesunzipped.org/ n.d.). These 
Internet sites were quickly located by most of the user participants. Members 
of the UK branch of the International Society of Genetic Genealogists 
(ISOGG) discovered the study website within hours of it going live. Some 
volunteered for the study or informed others about it. Other participants were 
either biosciences researchers who read the blog post on genomesunzipped 
or people known to participants, as snowball sampling was also used for 
recruitment (Atkinson and Flint 2001). Consequently, most of the group of 
user participants had similar characteristics to the early adopters described 
in McGowan et al’s study of DTCGT users in the USA (McGowan et al 
2010). The early adopter profile of this relevant social group suggests that 
they are likely to be more informed about the technology and to enthuse 
others. This was evident from the over-representation of participants who 
were working in genetic research and curious about DTCGT, or who were 
avid genetic genealogists. All the users had tested with 23andMe, having 
purchased a test from the company prior to changes made as a result of 
FDA intervention in 2013 (Conley 2013). Some had also tested with other 
companies for genetic genealogy information (see Table 1 for details). 
Seventeen interviews were conducted over four months in 2012, two on the 
telephone and fifteen face-to-face at the participants’ choice of location. 
 
Despite their known geographical locations, clinicians were more difficult to 
access. A number of strategies were used, including emails to British Society 
of Genetic Medicine Members (BSGM), leafleting delegates at a BSGM 
conference and contacting regional Genetics Services in the UK to raise 
awareness of the study. Recruitment initially targeted clinicians who had 
counselled patients about DTCGT, but was very slow. Subsequently it 
emerged that this was likely to be due to few referrals for DTCGT, despite 
concerns that clinical genetics services could be overwhelmed by requests 
for consultations with the worried well who struggled to interpret their 
genotyping report (Hogarth et al 2008). So the inclusion criteria were 
broadened to include clinicians who were willing to discuss their views about 
DTCGT, whether they had encountered patients who had sought counselling 
or not. This resulted in 16 interviews with genetics clinicians of various 
professions over eleven months between 2012  and 2013 at the participants’ 
choice of location. One was on the telephone, fifteen were face-to-face (see 
Table 2 for a summary of Genetics Clinicians’ Information).  
 
Interviews were semi-structured and in-depth, mixing specific and open 
questions as indicated by the participant’s experiences. Questions and 
prompts covered demographic information, types of testing used or 
encountered, referrals to discuss testing, people’s experiences of testing or 
counselling testers as well as general exploration of their views about 
DTCGT. Interviews were audio-recorded and I transcribed them to familiarise 
myself with data from the interviews onwards. Interviews commenced after 
participants had consented to participation including the use of verbatim, de-
identified excerpts. To maintain confidentiality, data extracts in this paper are 
attributed to user participants using synonyms and occupation, but to 
clinicians using an assigned code that identifies their place in the sequence 
of clinician participant (CP) interviews and their profession. These different 
approaches also maintain a distinction between the two groups in the data 
analysis.  
 
The transcript data were analysed with the principles of impartiality and 
symmetry in mind. This was deliberate in order to avoid attributing my own 
views to the participants and to enable me to adopt an objective and 
symmetrical approach to the data from the two relevant social groups studied 
here in relation to DTCGT specifically. An iterative approach was taken to 
the data analysis to elicit the themes within the texts of the interview 
conversations (Creswell 2013). Repeated reading of the text, making notes 
about patterns and disparities, and using reflective notes about the 
interviews informed my thinking with the data. The data were coded 
inductively with in vivo codes that emerged from the participants’ discourse 
(Ryan and Bernard 2000). The data were then re-read alongside the 
literature and deductively collected into categories. The final stage of 
analysis commenced by writing and connecting the categories and literature 
in a more direct manner. From this perspective I used further reading and 
writing to interact with the data and explore its categories alongside my 
thoughts (Coffey and Atkinson 1996). From this iterative process three 
overarching themes became evident across the participants’ data. These 
were  
1. Socialising DNA: the influence of social networks on the participants’ 
technological frame and discourse about DTCGT 
2. Personalising DNA: participants’ individual ideas about DNA in the 
context of SNP genotyping and their incorporation into participants’ 
genetic identities or clinical practice 
3. Testing the NHS: the problem of expectations for personalised 
medicine in the context of collective medicine provision  
The third theme of personalised medicine and its challenge for the NHS is 
the focus of this paper. 
 
Findings – Testing the NHS 
Public support for the NHS has been unstinting since its inception (Klein 
2013). Whilst not surprising, the organisation that the public champions is 
arguably more simplistic than the complex one in which so many have 
vested interests and for which there are different visions of its obligations 
and how to meet them. The two groups in this study volunteered opposing 
beliefs about personal genomics in the NHS context, illustrating the 
contested nature of commercial genotyping in this context. There was 
predictable support for personalised medicine (though not necessarily at 
NHS expense) from some DTCGT users, while clinicians described support 
for collective medicine and the need to protect the NHS’ scarce resources. 
Tensions between these two groups focused on responsibility, either for 
individual health or service provision, and the concepts of empowerment of 
the public versus professional expertise. Areas of agreement focused on 
pharmacogenomics and a shared support for the NHS, though these are 
unlikely to indicate imminent stabilisation of the technology. I shall discuss 
each of these sub-themes in turn, using excerpts from the data to illustrate 
the points made. 
 
Responsibility 
Discussion from some test users about personal information and 
responsibility for health suggests uptake of policy moves towards individuals 
taking more responsibility for their own health (Department of Health 2010). 
However, they also indicate adoption of companies’ tropes of personalisation 
and empowerment, which Van Lente suggests is due to technologies 
becoming fixed in specific language that directs beliefs and behaviour (Van 
Lente 2000). 
 
Users who referred to the health information from testing in relation to 
responsibility drew attention to the opportunity for making lifestyle alterations 
or seeking health screening based on the health information provided by 
DTCGT. One user had sought medical advice, as her test results suggested 
an increased risk of cancer (supporting her family history). Similarly, Ian, who 
does not have a background in genetics or biotechnology, stresses the need 
for cancer screening. 
 
“I must get my PSA count done, at my age I should be doing it 
anyway. I haven’t got any symptoms but I should and having got 
the information [from DTCGT] it’s really highlighted it to me that I 
should. I’m very aware of that but I haven’t done anything about 
it yet …” Ian (retired). 
 
This illustrates personal responsibility for health monitoring, not least 
perhaps because there is no effective screening programme for prostate 
cancer. However the value of PSA testing is unclear bringing Ian’s assertion 
into question (Public Health England 2016). Ian stresses his personal 
responsibility repeatedly. However, his lack of action is in common with other 
users none of whom described making lasting lifestyle changes or having 
interventions for disease risk management in light of test results. This 
supports findings in the study of early DTCGT adopters in the USA and the 
REVEAL study (McGowan et al 2010, Chilibeck et al 2011). It also refutes 
concerns about the impact on the NHS of concerned citizens seeking 
interventions following DTCGT that Dickenson forecasted (Dickenson 2013). 
 
Clinicians’ concerns in respect of responsibility were focused on providing 
genetic counselling and protecting the NHS from the repeatedly cited 
potential drain on scarce resources by privately-initiated testing (Nuffield 
Council of Bioethics 2010, Dickenson 2013). The clinicians who had 
counselled people following DTCGT voiced concerns. 
 
“One of the things I find difficult is that we get, when these things 
come up the people are very, very upset and they want to be dealt 
with on an urgent basis, and so that’s really expensive time, that 
kind of emergency time. And I find it really hard to justify taking up 
emergency time but I don’t want to see the patient suffering either.” 
CP2 (Doctor) 
 
This represents a unique reference to counselling someone in distress 
following DTCGT in this study. Patients’ distress is emphasised, as is their 
expectation for counselling, to highlight the moral challenge of juggling finite 
resources. This is framed in a manner that suggests this occurs more often 
than evidence suggests, possibly in a similar adoption of prevailing discourse 
about anticipated pressure on Genetics Services from DTCGT as users 
adoption of tropes of personalisation and empowerment. Concerns about 
use of scarce resources being taken up by counselling people who had 
initiated testing privately were more widely expressed despite little evidence 
of it. Most inferred that DTCGT was outside the remit of clinical genetics. 
This nurse defends the NHS responsibility for rationing, pointing to an 
impasse in balancing personalised and collective medicine. 
 
“If people … want to get their 23andMe, I‘m not bothered. I am 
bothered if they then use up healthcare resources to interpret 
findings that are meaningless for a test that wouldn’t be offered on 
the healthcare system. And you know I don’t know how we deal with 
that. I mean I don’t think this just applies to genetic tests. It applies 
to body scanning, it applies to lots of things.” CP5 (Nurse) 
 
An experienced doctor, with academic responsibilities in addition to a clinical 
role, expressed a more equivocal view. Arguments for both collective and 
personalised medicine are presented, possibly due to a strategic view of 
genomic technologies’ potential diagnostically and for NHS revenue 
generation through developing commercial biotechnology opportunities.  
 
“It comes down to whether you want to take a public health approach 
or an individual healthcare view of it and we all oscillate between 
those positions. There’s clearly a danger that unregulated, genetic 
testing causes a lot of people a lot of distress, exposes unrecognised 
non-paternities, makes people anxious who are already anxious 
which is why they did the test, doesn’t resolve their anxiety, it just 
makes them go to the doctor and pester him who then has an 
opportunistic cost because he’s so busy seeing that person that he 
doesn’t see the next one, and you can portray a very negative 
perspective. On the other hand you can also say that if you empower 
the individuals to care for themselves and make those tests available 
in a controlled way, quality control them well, we could massively 
expand genetic testing and people’s appreciation and understanding 
of it because it’ll touch more and more of their lives and you’ll just 
make it more and more part of routine healthcare which is where it’s 
now capable of moving. So I kind of sit in the optimistic let’s have a 
go camp.” CP10 (Doctor) 
 
The explicit references to both sides of the responsibility debate and the 
interpretative flexibility demonstrated in recognising that they are not 
mutually exclusive suggests a vision that supports genomic technologies 
generally rather than dismissing DTCGT. This locates DTCGT within the 
wider context of genomic technologies including Genome England’s 100,000 
Genomes Project and increasing use of genome sequencing in “mainstream 
medicine”, which are being forecast to shift genetics clinicians roles towards 
more educational and advisory responsibilities (www.genomicsengland.co.uk 
n.d., AGNC 2014:1, Clayton-Smith et al 2015).  
 
The suggestion that genomic information could be empowering depends on 
understanding genomics and its role in contributing to people’s health 
information. This could be interpreted as having expertise in genomics; the 
issue of how user and clinician participants equate this to clinical genetics 
expertise is explored next. 
 
Empowerment or Expertise 
Those of the study’s group of users with a primary interest in health results 
and genealogy expressed support for personalised health information 
commensurate with what Bunnik et al refer to as the personal utility of 
DTCGT (Bunnik et al 2015). Given NHS policies highlighting the importance 
of patient engagement and empowerment, people’s pursuit of health 
information from personal genomics is perhaps unsurprising. However, this 
has fuelled criticisms of healthcare professionals dismissive of patients’ 
efforts, owing to their paternalistic approach and ignorance of contemporary 
genotyping technologies (Jordens et al 2009, Bunnik et al 2015). Several 
users in this study were among them, voicing strong opinions about their 
perceptions of deficits in NHS staff knowledge and service provision. Their 
technological frame of DTCGT is that it provides important personal health 
information. It is worth remembering that at least half the group of users in 
the study have occupational experience of genetics, whilst those who are 
genealogists have experiential expertise in genotyping, having purchased 
more than one test. Whilst the group of clinicians all have the credentialed 
clinical genetics expertise that Collins and Evans describe, their experiential 
expertise of SNP genotyping was arguably not comparable to the users’ 
(Collins and Evans 2007). However their technological frame of DTCGT is of 
technology based on contingent science, one referring to it as “snake oil”. 
Not all were disparaging, but their view of DTCGT as providing meaningless 
information sets clinicians in opposition to those users whose technological 
frame of DTCGT saw it as empowering. 
 Several users voiced scepticism about doctors’ understanding of DTCGT,  
describing dismissive attitudes. This supports assertions that the 
democratisation of genomic information could erode trust between patients 
and healthcare professionals (McGuire and Burke 2008, Tutton 2014). The 
following excerpt is from a user who works in bioinformatics and had tested 
partly due to her curiosity about genomics as well as personal and familial 
health issues that she wished to investigate. This seems to have been driven 
by her need for autonomy so that she could access and consider her health 
information independently. 
 
“The health service seems to work with doctors being in charge with 
the patient being a kind of vessel that they look at and treat and 
examine; I rather baulk at that. I find it really frustrating and difficult 
to deal with, so I like having control over it and I’d rather skip the 
doctors giving me a pile of information I already know and 
sometimes don’t agree with, and I like to have the information there 
and be able to mull it over in my own time. I do find doctors’ 
appointments are really pressured as well, you get 10 minutes to 
talk to a Consultant sometimes and you have to say everything in 
that 10 minutes, coherently; and you don’t get another appointment 
for months for instance and it’s just a horrible, horrible experience … 
I think the medical profession ought to get with it, make use of it 
[genomics]. I think they are pretty stuck in the past. I think it’s 
appalling the lack of uptake of new technologies in the NHS. It’s just 
a huge big sluggish monster and they are barely doing any 
sequencing of people as far as I can tell. I don’t think they are any 
good at preventative or diagnostic medicine, it’s all reactive what the 
NHS does and I wish they’d get more proactive and do things ahead 
of time rather than letting people get ill and then put a sticking 
plaster over the top of it.” Laura (Biologist)  
 
Despite her self-knowledge and understanding of biology, Laura’s emphatic 
statement suggests that medical hegemony leaves her disempowered. The 
promise of personalisation and empowerment offered by DTCGT is attractive 
partly because it circumvents conventional medical power and gatekeeping, 
bolstering her sense of agency. However, her observation about medicine’s 
lack of integration of genomics to explain the NHS’ inability to help her 
appears to justify her use of DTCGT. Here, her flexible interpretation of 
genomics arguably equates DTCGT with sequencing and invests genomics 
with diagnostic potential that has yet to be realised (Tutton 2014). 
 
In contrast, clinicians questioned the value of SNP genotyping and some 
view public understanding of genetics with a deficit model compared to their 
clinical expertise. One genetic counsellor and a doctor implicitly position 
clinicians as having expertise. 
 
“People access tests for very different reasons and unfortunately I 
think the public do think it’s CSI.” CP1 (Scientist) 
 
This counsellor’s experience of patients’ understanding of genomics is 
equated with a popular television crime drama. The suggestion is that 
fictional representations of genetics are absorbed and repositioned as truth 
by people consulting clinical genetics services. Here the contingent nature of 
the scientific basis for DTCGT could be equated to fictional representations 
of science implying that clinical genetics expertise is needed to explain 
genetic information. Another clinician’s experiences also suggested that 
people view genetics deterministically. 
 
 “I think that people often start off in a position where genetics is 
really something very important and very deterministic. Umm, if they 
don’t start from that position then I’m not so worried about it but I 
think it’s really common in UK society to think that genetics 
determines much more than, much more in a clear way than I think 
it does” CP4 (Doctor) 
 
This view invests the majority of British society with deterministic 
understanding of genetics on the basis of this doctor’s experience, the 
implication being that DTCGT users could be misled and caused needless 
harm by DTCGT results. Indeed Harris et al’s argument that deterministic 
interpretation of genetic information is supported when accessed through the 
Internet strengthens this concern (Harris et al 2016). However, neither of 
these extracts indicate consideration for people represented by some users 
in this study who do have genomics knowledge and who felt they were able 
to understand their test results, nor the finding that none of the users, 
whatever their interpretation of DTCGT, reported experiencing significant or 
lasting concerns from testing. 
 
While some of these users’ views suggest a utopian view of personalised 
medicine that they criticise doctors for shunning, the clinicians’ support for 
collective medicine necessitates a different view of the utility of personal 
genomics. Juxtaposing these views results in on-going conflict between 
these relevant groups about the technological frame of DTCGT as well as 
having repercussions for the relationship of trust between patients and 
healthcare professionals as predicted (McGuire and Burke 2008, Wyatt et al 
2013). Brown and Webster suggest that where trust fails, healthcare practice 
is unfeasible and, whilst this point does not appear to have been reached by 
these participants, these excerpts do point to a shift in the clinician-patient 
relationship to a more distrusting position or at least a less readily assumed 
trust (Brown and Webster 2004). However, while SNP genotyping for 
common complex diseases has the potential to disrupt trust between 
patients and practitioners and fuel the on-going disputes about personal 
genomic technology, there are aspects on which participants in both groups 
shared common opinions, which I shall complete the discussion with. 
 
Common ground 
The data in this study suggested that some of the participants in both groups 
shared similar views about two areas relating to DTCGT in the NHS context. 
Firstly, there were shared understandings about the value and significance of 
the NHS both as the country’s principal healthcare provision and as an 
institution strongly associated with the UK’s national identity, endorsing 
Klein’s assertion that the NHS is a “national treasure” (Klein 2013:vi). 
Secondly, there were similar views among some participants in both groups 
about DTCGT’s pharmacogenomics information. 
 
Support for the NHS was evident in some participants’ references to 
examples from their practice or experience as users of the NHS to illustrate a 
shared perception of people’s preferences for its services over seeking 
healthcare information independently. Clinicians referred to people’s faith in 
the NHS based on their experiences as healthcare professionals. Whilst this 
may seem to be contradictory to the earlier suggestion that DTCGT users’ 
trust in the NHS is being challenged by personalised medicine, not all users 
expressed these views; some users were more equable. One genetics 
researcher was eager to separate her self-professed “narcissistic curiosity” in 
pursuing DTCGT from the NHS’ responsibilities. 
 
““The NHS doesn’t have the resources to do these things for people 
who are just interested or curious … here people really generally 
trust the NHS and I think most British people have huge affection for 
the NHS and there’s a lot of respect for it… it’s something we are 
really proud of and so we tend to trust the NHS, even though it’s not 
perfect.” Maria (Geneticist) 
 
The commonly described recreational aspect of personal genomics is often a 
motivation for testing, driven by people’s curiosity (Prainsack et al 2008). As 
with many other geneticists and genealogist users in this study, Maria 
viewed her test as satisfying her curiosity about her DNA rather than related 
to health care or substituting any NHS responsibility for her health. Her 
reference to the NHS’ lack of perfection suggests an acknowledgement that, 
despite its dissonance with the consumerism of personalised medicine, the 
collective medical model is acceptable and widely supported by the public 
because of its centrality to British national identity (Gershlick et al 2015). 
 
The second aspect of shared views about SNP genotyping was more 
surprising, being about pharmacogenomics, the information from SNPs that 
suggest variance in pharmacodynamics or kinetics (the physiological 
processes affected by drugs or those which metabolise them respectively). 
This could be seen as fortunate, given the dependence of patients on 
qualified healthcare professionals for prescribing of medicines. However, the 
contingent nature of the science underpinning disease-risk information from 
SNP genotyping is equally applicable to pharmacogenomics and arguably 
has more serious implications if prescribing decisions are made on the basis 
of its assumed utility.  
 
Richard Tutton’s exploration of the historical context of personalised 
medicine refers to the rhetorical devices used to promote the compelling idea 
that pharmacogenomics will result in drug treatments designed for 
individuals rather than populations (Tutton 2012). The expectation that 
genomics will deliver individually designed drug regimens in a new molecular 
iteration of personalised medicine has not been realised. It has resulted in 
the concept being modified along more achievable lines, such as stratified 
medicine where people are assigned to groups of treatment according to 
genetic differences (Tutton 2014). In light of this it is significant that some 
participants in both the relevant social groups being studied spoke positively 
about the potential of pharmacogenomics to improve health care. The 
following extracts from one user of DTCGT and one clinician illustrate this 
point. The first is from a researcher in public health who envisages 
negotiating her future drug therapy with her GP. 
 
“On my genetic thing it says there’s a sensitivity to Metformin. I 
obviously get it from my mother [who reacted badly to it] and 
Metformin is such a typical drug for giving to type II diabetic patients 
so it’s going to be interesting if I ever get to the point of having a GP 
say he’s going to put me on Metformin, [I wonder] how much notice 
he’s going to take when I say “I don’t think so”. Carol (Public Health 
researcher) 
 
Carol’s suggestion about her future treatment envisages a confrontational 
consultation and prescription without any discussion or consideration of 
concordance. Her refusal of it based on her pharmacogenetics SNP analysis 
illustrates her use of interpretative flexibility in relation to DTCGT. She had 
earlier dismissed results relating to disease risk because of the inconclusive 
nature of SNP genotyping but seems to be more deterministic about the 
pharmacogenetics information. Carol’s justification for this on the basis of her 
DTCGT results ignores her family history of intolerance of this drug. Family 
history is thought to be more reliable than SNP genotyping in health 
information and is probably contributing to her thinking in this regard, though 
here she chooses to focus on her DTCGT results. 
 
Some clinicians also demonstrated interpretative flexibility in referring to 
pharmacogenomics positively, having dismissed its utility for common 
complex disease risk information. One doctor gave a colourful vision of his 
ideas for anticoagulant prescribing on the basis of SNP genotyping. 
“I can see the value in these types of things; you know Warfarin, 
[prescribing] Warfarin’s a black art. When I worked on the wards I 
was told, “Start this guy on Warfarin. Prescribe him 10 [mg] today, 
10 tomorrow and 5 the day after that and test his INR [blood clotting 
time].” And you’d test their INR and some guy’s INR hadn’t shifted 
from baseline so you’d whack them another 10 and some little old 
woman was ready to bleed out all over the ward because her blood 
was so thin, it was like dilute orangeade. So it was a guess, but now 
we’re getting a handle on that. A little bedside SNP so we’d know 
how to prescribe, and then start them on Warfarin. But that’s not 
predicting a genetic disease; we need this information to look at how 
to dose you.” CP13 (Doctor) 
Titrating this risky anticoagulant medication within the narrow margins of safe 
efficacy indicates the clinical challenge involved and its associated stress. 
Using interpretative flexibility this doctor imagines a solution to that 
challenge. However, this potential clinical application for SNP genotyping in 
the NHS is not so far supported by research. Genotyping patients for 
Warfarin metabolism and prescribing dosage accordingly does not appear to 
make any significant difference to the efficacy or safety of this difficult and 
potentially dangerous treatment (Stergiopoulos and Brown 2014). This casts 
doubt on the efficacy of point-of-care SNP genotyping for Warfarin dosing, 
supporting concerns about clinicians’ lack of knowledge in this regard (UK 
Pharmacogenetics Study Group 2006).  
 
Participants’ mutual support for pharmacogenomics could represent a point 
from which the relevant social groups involved in DTCGT in the UK could 
negotiate socially acceptable aspects of genomics technology in the NHS in 
future. This could provide an opportunity for stabilisation of the technology, 
as Hedgecoe and Martin (2003) argued in relation to pharmacogenomics. 
However, the likelihood of this is small and its foundations are tenuous in the 
extreme, given the contested basis of personalised medicine in the context 
of SNP genotyping in particular, as these findings show. 
 
Conclusion 
Findings from this study suggest that DTCGT is a less disruptive 
technology in the UK context than early concerns forecast. This is 
evidenced firstly by the study’s group of users’ lack of concern or uptake 
of interventions on the basis of test results. Secondly, the lack of impact 
on NHS clinical genetics services is demonstrated by difficulties 
recruiting genetics clinicians with experience of DTCGT to the study and 
participants’ reports of few enquiries about post-DTCGT counselling. 
However, this should not obscure the conflict between some of the 
participants in relation to the NHS context, which focused on the tension 
between personalised and collective medicine, responsibility and 
expertise.  
 
The issue of who should take responsibility for individuals’ health is 
being exposed by DTCGT and, as Klein suggests, the NHS is currently 
in an ambiguous position in this regard (Klein 2013). The concepts of 
personalisation and consumerism and the associated expectation of 
public responsibility are particularly challenging for the NHS in times of 
austerity. Arguably this is the predictable outcome of health policy that 
has increasingly emphasised health promotion, individual responsibility 
and choice, rhetorically at least (Klein 2013). Thus it is not unreasonable 
of people to avail themselves of opportunities to obtain health 
information and to feel aggrieved when their efforts are dismissed by 
healthcare professionals. Equally understandable are healthcare 
professionals’ frustrations about the lack of transparency of commercial 
health information marketing and the significant restraints within which 
they are expected to provide services to an increasingly demanding 
public, some of whom appear to show little genuine engagement with 
responsibility for their health. This lack of engagement is despite 
adopting the language of commercial genomics companies in relation to 
DTCGT and using interpretative flexibility to assume belief in the 
promise of DTCGT technology to provide personalised health 
information. 
 
Users’ experiential expertise is important in considering their level of 
engagement and understanding of what their genomic data is 
communicating. Most users in this study have knowledge of genetics 
from personal research or education, and have spent considerable time 
immersed in learning about personal genomics either independently or 
through their occupation. In addition their networking activities have 
facilitated the dissemination and development of what has been referred 
to as “technical know-how” (Evans and Plows 2007:836). Users’ 
experiences of DTCGT could be referred to as lay-expertise, in a 
manner similar to studies by Kerr et al about the public and their 
knowledge of genetics, Prior’s work on lay-expertise in medical 
sociology and Epstein’s work with HIV-AIDS activists (Epstein 1995, 
Kerr et al 1998, Prior 2003). However, as these authors all indicate, ‘lay-
expertise’ belies the complexity inherent in who lay actors are and what 
constitutes their expertise, as exemplified by the heterogeneous nature 
of this study’s group of users. In addition, investing users with expertise 
could be questioned in light of the interpretative flexibility demonstrated 
by some when extolling the virtues of their DTCGT information. Whilst 
their expertise in clinical genetics both unites the clinicians and informed 
their inclusion as a relevant social group for this study, their expertise in 
personal genomics is also questionable. Although credentialed, 
contributory experts in clinical genetics, most clinicians’ experience and 
expertise relates to chromosomal abnormalities and genetic mutations 
rather than SNP genotyping. Some are well versed in the literature 
relating to genomics and are able to cut through users’ apparent 
experiential expertise by critiquing the scientific basis of testing, the 
panels used for SNP analysis and the lack of inclusion of wider genetic 
anomalies related to specific conditions. However, they are mostly not 
engaged with the public who are buying DTCGT. Whether expert or not, 
understanding of personal genomics influences participants’ 
technological frames of DTCGT, setting many of them apart into those 
who support the personal utility of DTCGT and those who dismiss it as 
lacking utility and a threat to collective medicine. 
 
Analysing the views of users and genetic clinicians about DTCGT and the 
challenges for the NHS suggests that the potential for SNP genotyping 
technology to achieve stability in a healthcare context in the UK is probably 
remote. While the relevant social groups in this study may suggest that 
DTCGT is a focus for the on-going disputes around personalised versus 
collective medicine in the UK, I would argue that DTCGT per se is not the 
cause of that dispute. Rather it is the vehicle for participants’ expressions of 
concern as they are confronted with challenges to their respective 
perceptions of responsibility for health. Shared appreciation of the NHS was 
evident in both groups and some clinicians’ interpretative flexibility in relation 
to pharmacogenomics led to common visions with some users for its future 
potential. However, I would argue that these aspects of common ground are 
unlikely in themselves to lead to a resolution of the disputes about DTCGT in 
the near future, given the generally irreducible nature of the differences 
between these two groups’ views about responsibility and empowerment. It 
is more likely that the technology will be stabilised by virtue of being 
superseded by new problems such as whole genome sequencing and 
expectations of the information it will yield.  
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Table 1: User Participants’ Demographic and DTCGT Information 
Age (years) Range 
Mean 
Median  















Ethnicity White British  
Irish    


















Occupation Genetics research 






DTCGT type 23andMe 
FTDNA 
Sorenson Y DNA 
Sorenson Surname DNA 
Autosomal DNA 
Oxford Ancestry 








Number of tests 
each 
5 tests 
3 tests  
2 tests 






 Table 2: Genetics Clinicians’ Professional Information and 























Types of DTCGT 
consulted about 
SNP genotyping 






Single gene sequence 
 












about DTCGT  
(NHS unless specified 
otherwise) 
Own test  
 
Relatives’ test  
 
Own test (private 
consultations for 
journalists 
investigating DTCGT) 
6 
 
2 
 
3 
 
